RxDoctor Payments Data

Jeffrey Pape

Optometrist · Norfolk, NENPI 1073627352

Payments from drug & device makers

$1,776in general payments, 2019–2025

Across 67 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$495
  • Alcon$371
  • AbbVie$173
  • Sun Pharmaceutical Industries Inc.$126
  • Mallinckrodt Hospital Products Inc.$117
  • Oyster Point Pharma, Inc.$93
  • plus $402 from 10 others

What the payments were for

  • Food & beverage$1,776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,776 in reported general payments places this provider in the 80th percentile of 383 optometrist providers in Nebraska.

See all optometrist providers in Nebraska

Medicare billing

Part B allowed, 2024
$128,604
Medicare patients
531
Services billed
1,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine16$21,381
LumiganBimatoprost18$8,214
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$4,217
SimbrinzaBrinzolamide/Brimonidine Tart14$2,908
Loteprednol Etabonate19$2,724
CombiganBrimonidine Tartrate/Timolol15$2,694
Latanoprost178$1,301
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$1,144
Fluorometholone17$854
Prednisolone Acetate21$539
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$500
Brimonidine Tartrate34$442
Timolol Maleate51$436
MoxifloxacinMoxifloxacin Hcl19$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$173$32,28949 claims
AlconSimbrinza$371$2,90814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 383 optometrist providers in Nebraska.

Other optometrist in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →